These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 12960349)

  • 1. Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130.
    Nowell MA; Richards PJ; Horiuchi S; Yamamoto N; Rose-John S; Topley N; Williams AS; Jones SA
    J Immunol; 2003 Sep; 171(6):3202-9. PubMed ID: 12960349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential regulation of neutrophil-activating chemokines by IL-6 and its soluble receptor isoforms.
    McLoughlin RM; Hurst SM; Nowell MA; Harris DA; Horiuchi S; Morgan LW; Wilkinson TS; Yamamoto N; Topley N; Jones SA
    J Immunol; 2004 May; 172(9):5676-83. PubMed ID: 15100312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The IL-6/sIL-6R complex as a novel target for therapeutic approaches.
    Rose-John S; Waetzig GH; Scheller J; Grötzinger J; Seegert D
    Expert Opin Ther Targets; 2007 May; 11(5):613-24. PubMed ID: 17465721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 trans-signaling: implications in the pathogenesis of rheumatoid arthritis.
    Nowell MA; Richards PJ; Fielding CA; Ognjanovic S; Topley N; Williams AS; Bryant-Greenwood G; Jones SA
    Arthritis Rheum; 2006 Jul; 54(7):2084-95. PubMed ID: 16802343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-6 signalling in juvenile idiopathic arthritis is limited by proteolytically cleaved soluble interleukin-6 receptor.
    Peake NJ; Khawaja K; Myers A; Nowell MA; Jones SA; Rowan AD; Cawston TE; Foster HE
    Rheumatology (Oxford); 2006 Dec; 45(12):1485-9. PubMed ID: 16690760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo and in vitro activities of the gp130-stimulating designer cytokine Hyper-IL-6.
    Peters M; Blinn G; Solem F; Fischer M; Meyer zum Büschenfelde KH; Rose-John S
    J Immunol; 1998 Oct; 161(7):3575-81. PubMed ID: 9759879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-17-mediated monocyte migration occurs partially through CC chemokine ligand 2/monocyte chemoattractant protein-1 induction.
    Shahrara S; Pickens SR; Mandelin AM; Karpus WJ; Huang Q; Kolls JK; Pope RM
    J Immunol; 2010 Apr; 184(8):4479-87. PubMed ID: 20228199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis.
    Nowell MA; Williams AS; Carty SA; Scheller J; Hayes AJ; Jones GW; Richards PJ; Slinn S; Ernst M; Jenkins BJ; Topley N; Rose-John S; Jones SA
    J Immunol; 2009 Jan; 182(1):613-22. PubMed ID: 19109195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation.
    Kotake S; Sato K; Kim KJ; Takahashi N; Udagawa N; Nakamura I; Yamaguchi A; Kishimoto T; Suda T; Kashiwazaki S
    J Bone Miner Res; 1996 Jan; 11(1):88-95. PubMed ID: 8770701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo.
    Atreya R; Mudter J; Finotto S; Müllberg J; Jostock T; Wirtz S; Schütz M; Bartsch B; Holtmann M; Becker C; Strand D; Czaja J; Schlaak JF; Lehr HA; Autschbach F; Schürmann G; Nishimoto N; Yoshizaki K; Ito H; Kishimoto T; Galle PR; Rose-John S; Neurath MF
    Nat Med; 2000 May; 6(5):583-8. PubMed ID: 10802717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation.
    Hurst SM; Wilkinson TS; McLoughlin RM; Jones S; Horiuchi S; Yamamoto N; Rose-John S; Fuller GM; Topley N; Jones SA
    Immunity; 2001 Jun; 14(6):705-14. PubMed ID: 11420041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble IL-6 receptor induces calcium flux and selectively modulates chemokine expression in human dermal fibroblasts.
    Spörri B; Müller KM; Wiesmann U; Bickel M
    Int Immunol; 1999 Jul; 11(7):1053-8. PubMed ID: 10383937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-6 and its receptor: from bench to bedside.
    Scheller J; Rose-John S
    Med Microbiol Immunol; 2006 Dec; 195(4):173-83. PubMed ID: 16741736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-6 transsignaling: the in vivo consequences.
    Jones SA; Richards PJ; Scheller J; Rose-John S
    J Interferon Cytokine Res; 2005 May; 25(5):241-53. PubMed ID: 15871661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of CD4+ T cell IL-6R expression during inflammation underlines a role for IL-6 trans signaling in the local maintenance of Th17 cells.
    Jones GW; McLoughlin RM; Hammond VJ; Parker CR; Williams JD; Malhotra R; Scheller J; Williams AS; Rose-John S; Topley N; Jones SA
    J Immunol; 2010 Feb; 184(4):2130-9. PubMed ID: 20083667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No inhibition of IL-27 signaling by soluble gp130.
    Scheller J; Schuster B; Hölscher C; Yoshimoto T; Rose-John S
    Biochem Biophys Res Commun; 2005 Jan; 326(4):724-8. PubMed ID: 15607729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel path to activation of vascular smooth muscle cells: up-regulation of gp130 creates an autocrine activation loop by IL-6 and its soluble receptor.
    Klouche M; Bhakdi S; Hemmes M; Rose-John S
    J Immunol; 1999 Oct; 163(8):4583-9. PubMed ID: 10510402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Signal through gp130 activated by soluble interleukin (IL)-6 receptor (R) and IL-6 or IL-6R/IL-6 fusion protein enhances ex vivo expansion of human peripheral blood-derived hematopoietic progenitors.
    Kimura T; Wang J; Minamiguchi H; Fujiki H; Harada S; Okuda K; Kaneko H; Yokota S; Yasukawa K; Abe T; Sonoda Y
    Stem Cells; 2000; 18(6):444-52. PubMed ID: 11072033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the mechanism of action of anti-human interleukin-6 and anti-human interleukin-6 receptor-neutralising monoclonal antibodies.
    Kalai M; Montero-Julian FA; Brakenhoff JP; Fontaine V; De Wit L; Wollmer A; Brailly H; Content J; Grötzinger J
    Eur J Biochem; 1997 Nov; 249(3):690-700. PubMed ID: 9395315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-6 trans-signalling in chronic inflammation and cancer.
    Scheller J; Ohnesorge N; Rose-John S
    Scand J Immunol; 2006 May; 63(5):321-9. PubMed ID: 16640655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.